MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
about
Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.An update on TroVax for the treatment of progressive castration-resistant prostate cancerA pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.TroVax(®) vaccine therapy for renal cell carcinoma.Emerging immunotherapies for renal cell carcinoma.Evolving Immunotherapy Approaches for Renal Cell Carcinoma.5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.
P2860
Q34260594-EB0666FB-8AB7-4978-AAE2-5C81E5C6A462Q35050205-4DD62553-4637-4C9E-9042-F57F3C0804ECQ35582228-1FD33CA8-FBD0-4C0D-938B-2B0E742721C8Q36043852-D93857F3-074E-4161-AA58-4270B08F56CBQ36391900-7F52CE6C-6620-4373-8117-536D92021B7FQ37965748-AB0C0BCA-F7D6-4BBF-90B7-5EA1E53E87CCQ38037491-A7C18021-683F-4F44-A4E5-9D493A535F14Q38913703-175B9E5E-41F0-4E66-8AB2-1B7591CCB603Q38984929-F015B184-2B9B-4D48-85EC-6A72AB07F3F8Q42282117-5A0B6928-E829-42C7-90A6-798A1764C459Q45025116-1FFDE08A-7048-4C72-8B0B-229C58645314Q47630188-B6728873-53FF-4491-BB43-E7BA64C4B5C3Q55026505-9DC354F3-B375-4E0C-ADA6-553D9250011FQ55026796-23714889-EC85-4B40-A7D2-3CB33CCCA9B4
P2860
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
MVA-5T4-induced immune respons ...... cacy in renal cancer patients.
@en
MVA-5T4-induced immune respons ...... cacy in renal cancer patients.
@nl
type
label
MVA-5T4-induced immune respons ...... cacy in renal cancer patients.
@en
MVA-5T4-induced immune respons ...... cacy in renal cancer patients.
@nl
prefLabel
MVA-5T4-induced immune respons ...... cacy in renal cancer patients.
@en
MVA-5T4-induced immune respons ...... cacy in renal cancer patients.
@nl
P2093
P2860
P1476
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients
@en
P2093
Howard L Kaufman
Jackie de Belin
Madusha Goonewardena
Michelle Kelleher
Mike McDonald
Richard Harrop
Robert E Hawkins
Robert J Amato
Stuart Naylor
William H Shingler
P2860
P2888
P304
P356
10.1007/S00262-011-0993-7
P577
2011-03-09T00:00:00Z